Canagliflozin Reduces Kidney-Related Adverse Events in Type 2 Diabetes and CKD: Findings From the Randomized CREDENCE Trial
Publication date: Available online 23 May 2021Source: American Journal of Kidney DiseasesAuthor(s): Hiddo J.L. Heerspink, Megumi Oshima, Hong Zhang, Jingwei Li, Rajiv Agarwal, George Capuano, David M. Charytan, Jagriti Craig, Dick de Zeeuw, Gian Luca Di Tanna, Adeera Levin, Bruce Neal, Vlado Perkovic, David C. Wheeler, Yshai Yavin, Meg J. Jardine
Source: American Journal of Kidney Diseases - Category: Urology & Nephrology Source Type: research
More News: Canagliflozin | Diabetes | Diabetes Type 2 | Endocrinology | Invokana | Urology & Nephrology